New pill taken every other day could prevent migraines

NCT ID NCT06409832

Recruiting now Disease control Sponsor: University of Florence Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether the drug rimegepant, taken as a tablet every other day, can help prevent migraines in adults who have at least four migraine days per month. Researchers will track changes in migraine frequency over three to twelve months. The goal is to see if rimegepant is effective and well-tolerated for long-term use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rimegepant 75 mg orally disintegrating tablet
What this could lead to: If it works, this could provide a new, well-tolerated option for preventing migraines in people who have frequent attacks.
What could go wrong: This is an early-stage observational study with only 100 participants, so results may not apply to everyone. Rimegepant may not reduce migraine days for all users, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache Headache Disorders, Secondary migraine disorder migraine with aura migraine without aura Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MIGRAINE MIGRAINE MIGRAINE WITH AURA MIGRAINE WITHOUT AURA

Contacts and locations

Locations

IRCCS National Neurological Institute "C. Mondino" Foundation
RECRUITING

Pavia, Pavia, 27100, Italy
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
RECRUITING

Florence, Florence, 50134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.